How the Dogs performed in 2025 (the setup for 2026)

In 2025, the Dogs had a strong year.

Using year-end data, the Dogs of the Dow (as selected on 12/31/2024) posted a +15.0% price return in 2025, compared with +13.0% for the Dow 30 and the DJIA itself on a price basis.

A few standouts helped carry the basket:

• 
  

  Johnson & Johnson: +43.1% in 2025 (price change)

  
  


• 
  

  IBM: +34.7%

  
  


• 
  

  Cisco: +30.1%

  
  


• 
  

  Amgen: +25.6%

  
  

And importantly, only one of the 2025 Dogs finished negative on a price basis:

• 
  

  Procter & Gamble: -14.5%

  
  

When you add dividends, the gap can look even better. One analysis calculated the Dogs’ 2025 total return at ~18.9%, ahead of the DJIA and roughly in line with or better than major benchmarks depending on the measurement window.

That matters for 2026 because strong performance in one year often reshuffles the list. Winners tend to see yields compress (prices rise faster than dividends), and laggards tend to rotate in.

The official Dogs of the Dow list for 2026

The official 2026 Dogs of the Dow are the 10 highest-yielding Dow components based on the close of December 31, 2025.

Here is the 2026 list (yields are from the end of the year):

1. 
   

   Verizon (VZ) — 6.78%

   
   


2. 
   

   Chevron (CVX) — 4.49%

   
   


3. 
   

   Merck (MRK) — 3.23%

   
   


4. 
   

   Amgen (AMGN) — 3.08%

   
   


5. 
   

   Procter & Gamble (PG) — 2.95%

   
   


6. 
   

   Coca-Cola (KO) — 2.92%

   
   


7. 
   

   UnitedHealth (UNH) — 2.68%

   
   


8. 
   

   Home Depot (HD) — 2.67%

   
   


9. 
   

   Nike (NKE) — 2.57%

   
   


10. 
    

    Johnson & Johnson (JNJ) — 2.51%

    
    

A quick observation: compared to 2025, UNH, HD, and NKE are the notable additions—each reflecting meaningful 2025 price weakness that pushed yields higher.

The “Small Dogs” angle (optional but widely followed)

A common variation is the Small Dogs of the Dow: the five Dogs with the lowest share prices at selection time, which some investors use as a tilt toward deeper value. On 12/31/2025, those were: VZ, MRK, PG, KO, and NKE.

Why the Dogs can work (and why they sometimes don’t)

The strategy is popular for a reason: it’s rules-based, transparent, and easy to execute.

Why it can outperform:

• 
  

  Mean reversion: blue-chip laggards often recover when the market stops punishing them.

  
  


• 
  

  Dividend support: yield can cushion drawdowns and reduce the “need” to time the market perfectly.

  
  


• 
  

  Valuation discipline: by construction, you’re often buying stocks that are cheaper than their peers.

  
  

Why it can underperform:

• 
  

  Value traps exist. A high yield can signal genuine business deterioration.

  
  


• 
  

  Sector concentration risk. Some years the Dogs become overloaded in a few sectors (e.g., energy/healthcare/consumer).

  
  


• 
  

  Dividend risk. If a company cuts its dividend, the key pillar of the strategy breaks.

  
  

This mixed track record is well documented. Investopedia notes Dogs of the Dow returns can be close to the DJIA over long periods, but performance varies materially depending on the timeframe studied. And recent years provide a perfect example: Barron’s reported that the 2024 Dogs materially lagged broader markets, even though 2025 then proved strong.

How to implement the 2026 Dogs strategy

If you want to keep it pure and rules-based, the classic approach looks like this:

1. 
   

   At the start of 2026, buy the 10 Dogs in equal dollar amounts.

   
   


2. 
   

   Hold for one year, collecting dividends.

   
   


3. 
   

   At year-end (late 2026 / early 2027), rebalance into the next Dogs list.

   
   

Practical guardrails

To keep the strategy from turning into a headache:

• 
  

  Rebalance once per year (don’t overtrade it).

  
  


• 
  

  Treat it as a basket strategy—avoid “falling in love” with one Dog.

  
  


• 
  

  Use position sizing that reflects the fact that Dogs can be equity-volatile even with dividends.